Evidence that the ginkgo biloba extract, EGb 761, neither accelerates nor enhances the rapid compensation of the static symptoms of unilateral vestibular deafferentation in guinea pig.

The concentrated Ginkgo biloba extract, EGb 761, has previously been reported to enhance and accelerate vestibular compensation following unilateral vestibular deafferentation (UVD), in particular, compensation of the dynamic postural symptoms such as locomotor dysequilibrium. However, many of these studies have not included a complete analysis of the static symptoms of UVD, such as spontaneous nystagmus (SN), yaw head tilt (YHT), and roll head tilt (RHT), nor have they included a dose-response analysis or vehicle controls for EGb 761. The aim of the present study was to examine the effects of the EGb 761 extract on static vestibular compensation in guinea pig, using a dose-response analysis and both vehicle and saline controls. Analysis of variance showed that there was a significant decrease in SN frequency (P < 0.05) and a significant change in the rate of SN compensation (P < 0.05), using 3 i.p. injections of EGb 761 (25, 50, or 100 mg/kg), or vehicle, or saline, at 0, 25, and 40 h post-UVD. However, post-hoc testing revealed that this was due entirely to significant differences between the saline and vehicle groups at 35, 40, and 50 h post-UVD (P < 0.05 in all cases) and between the saline and the 100 mg/kg and 25 mg/kg EGb 761 groups at 35 and 50 h post-UVD, respectively (P < 0.05 for both comparisons); there were no significant differences between the vehicle and drug groups at any time. YHT and RHT were not significantly different between the drug, saline, and vehicle groups. In a second set of experiments, the 50 and 100 mg/kg EGb 761 i.p. injection frequencies were doubled. However, once again, neither SN nor YHT were significantly different between the EGb 761 groups and the vehicle controls. These results suggest that 1) EGb 761 does not significantly enhance or accelerate compensation of the static symptoms of UVD in guinea pig and 2) the EGb 761 vehicle may exert some effects on its own. Therefore, EGb 761 may be of limited use in the treatment of acute vestibular dysfunction in humans.

The neuroprotective properties of the Ginkgo biloba leaf: a review of the possible relationship to platelet-activating factor (PAF).

Ginkgo biloba (Ginkgoaceae) is an ancient Chinese tree which has been cultivated and held sacred for its health-promoting properties. There is substantial experimental evidence to support the view that Ginkgo biloba extracts have neuroprotective properties under conditions such as hypoxia/ischemia, seizure activity and peripheral nerve damage. Research on the biochemical effects of Ginkgo biloba extracts is still at a very early stage. One of the components of Ginkgo biloba, ginkgolide B, is a potent platelet-activating factor (PAF) antagonist. Although the terpene fraction of Ginkgo biloba, which contains the ginkgolides, may contribute to the neuroprotective properties of the Ginkgo biloba leaf, it is also likely that the flavonoid fraction, containing free radical scavengers, is important in this respect. Taken together, the evidence suggests that Ginkgo biloba extracts are worthy of further investigation as potential neuroprotectant agents.

Can vestibular compensation be enhanced by drug treatment? A review of recent evidence.

Unilateral vestibular deafferentation (UVD) causes ocular motor and postural disorders, some of which disappear over time in a process of behavioral recovery known as vestibular compensation. This review summarises and evaluates the present status of drugs which enhance the vestibular compensation process either by reducing the initial symptoms of UVD or by accelerating the compensation process. Three classes of drugs are selected for review because of the amount of experimental evidence relating to them and because they are, for the most part, safe for use in humans: melanotropic peptides, calcium antagonists and gangliosides/Ginkgo Biloba extract EGb 761. It is concluded that the evidence supporting the efficacy of the melanotropic peptides and the Ginkgo Biloba extract EGb 761 in accelerating compensation is the most convincing; by comparison, the evidence relating to the effects of calcium antagonists on vestibular compensation is more controversial.